Treatment Outcomes of Second-Line Systemic Therapy for Neuroendocrine Prostate Cancer: A Report of Four Cases.
J UOEH
; 46(1): 23-28, 2024.
Article
em En
| MEDLINE
| ID: mdl-38479871
ABSTRACT
Neuroendocrine prostate cancer (NEPC) is a histological variant of prostate cancer and is characterized by aggressiveness and poor clinical outcomes. NEPC usually develops as a mechanism of treatment resistance in patients receiving hormone therapy for advanced prostate cancer. NEPC is sensitive to primary platinum-based chemotherapy, and has a short response duration. Second-line therapy is required in many cases, but clinical data on subsequent treatment after progression to first-line chemotherapy is limited. Here we report our experience of four cases of NEPC treated with second-line chemotherapy. Progression-free and overall survival rates were very low in three of the patients. One patient received multidisciplinary therapy using systemic and local chemotherapy and radiation therapy and survived for 24 months after initiation of second-line chemotherapy. Multidisciplinary therapy with chemotherapy and radiation is a promising option for improving the survival of patients with NEPC.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Carcinoma Neuroendócrino
Limite:
Humans
/
Male
Idioma:
En
Revista:
J UOEH
Ano de publicação:
2024
Tipo de documento:
Article